1. Home
  2. SPRO vs ZVIA Comparison

SPRO vs ZVIA Comparison

Compare SPRO & ZVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.58

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Logo Zevia PBC

ZVIA

Zevia PBC

HOLD

Current Price

$1.69

Market Cap

126.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
ZVIA
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
126.3M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
SPRO
ZVIA
Price
$1.58
$1.69
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$4.93
AVG Volume (30 Days)
1.9M
1.4M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
55.88
EPS
N/A
N/A
Revenue
$66,802,000.00
$161,259,000.00
Revenue This Year
N/A
$8.30
Revenue Next Year
$300.00
$6.87
P/E Ratio
N/A
N/A
Revenue Growth
39.24
4.01
52 Week Low
$1.52
$1.11
52 Week High
$3.08
$3.63

Technical Indicators

Market Signals
Indicator
SPRO
ZVIA
Relative Strength Index (RSI) 26.06 55.73
Support Level N/A $1.60
Resistance Level $2.45 $1.94
Average True Range (ATR) 0.14 0.11
MACD -0.05 -0.00
Stochastic Oscillator 8.93 40.74

Price Performance

Historical Comparison
SPRO
ZVIA

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

Share on Social Networks: